Cargando…

Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial

Retrospective analyses in non-randomised cohorts suggest that regimens containing fludarabine/Ara C and/or idarubicin/ara C may be more effective than daunorubicin/AraC (DA)-containing regimens in cases of acute myeloid leukaemia (AML) overexpressing p-glycoprotein (Pgp). We prospectively measured P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pallis, M, Hills, R, White, P, Grundy, M, Russell, N, Burnett, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255268/ https://www.ncbi.nlm.nih.gov/pubmed/22829167 http://dx.doi.org/10.1038/bcj.2011.23

Ejemplares similares

P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPA
por: Grundy, Martin, et al.
Publicado: (2011)

Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)
por: Arber, Daniel A, et al.
Publicado: (2020)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018)

P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
por: Potter, Nicola, et al.
Publicado: (2023)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Sweet’s Syndrome (SS) in the Course of Acute Myeloid Leukaemia (AML)
por: Guarneri, Claudio, et al.
Publicado: (2018)

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
por: Burnett, A K, et al.
Publicado: (2017)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014)

Immunophenotypic characterisation of morphologically diagnosed cases of Acute Myeloid Leukaemia (AML)
por: Basharat, Maria, et al.
Publicado: (2019)

Transcriptomic and proteomic analysis of mouse radiation-induced acute myeloid leukaemia (AML)
por: Badie, Christophe, et al.
Publicado: (2016)

The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities
por: Chilton, L, et al.
Publicado: (2016)

Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
por: Grundy, Martin, et al.
Publicado: (2018)

PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML
por: Verbiest, Tom, et al.
Publicado: (2015)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan
por: Huang, Huai-Hsuan, et al.
Publicado: (2022)

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
por: Jawad, Mays, et al.
Publicado: (2012)

A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7)
por: Karkuzhali, Ponnuswamy, et al.
Publicado: (2013)

A molecular signature of dormancy in CD34(+)CD38(-) acute myeloid leukaemia cells
por: Al-Asadi, Mazin Gh., et al.
Publicado: (2017)

Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML
por: Lee, Yoo Jin, et al.
Publicado: (2011)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
por: Tang, Ruoping, et al.
Publicado: (2008)

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
por: Ganzel, Chezi, et al.
Publicado: (2020)

Induction of Resistance Against Isotransplantation of Virus-Induced Myeloid Leukaemias
por: Pasternak, G., et al.
Publicado: (1963)

Phenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 Phosphorylation
por: Pallis, Monica, et al.
Publicado: (2016)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
por: Short, J. M., et al.
Publicado: (2023)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
por: Pan, Hong, et al.
Publicado: (2023)

Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
Publicado: (1980)

Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
Publicado: (1980)

A Comparison of Inpatient and Outpatient-Based Chemotherapy Regimens for the Treatment of Acute Myeloid Leukaemia In The Elderly
por: Daly, A.B., et al.
Publicado: (2019)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial
por: Jädersten, Martin, et al.
Publicado: (2022)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

Transformation of cytogenetically normal chronic myelomonocytic leukaemia to an acute myeloid leukaemia and the emergence of a novel +13,+15 double trisomy resulting in an adverse outcome
por: McGrattan, Peter, et al.
Publicado: (2007)

Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells
por: Grundy, Martin, et al.
Publicado: (2018)

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
por: Burnett, Alan K, et al.
Publicado: (2018)

Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2013)

Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8
por: Matsushita, H, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_ncbtgc0mt34jcbhrj5nrojd20u